Previous close | 5.40 |
Open | 5.40 |
Bid | 4.65 |
Ask | 5.25 |
Strike | 520.00 |
Expiry date | 2025-01-17 |
Day's range | 5.40 - 5.40 |
Contract range | N/A |
Volume | |
Open interest | 593 |
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.